Three of the Most Viral Claims About the Coronavirus Are Fake

Cures, dangers, and something called the “r-nought.”

A laboratory operator wearing a protective gear handles patients' samples in a laboratory of the National Reference Center (CNR) for respiratory viruses—including coronavirus—at the Institut Pasteur in Paris on January 28, 2020.Thomas Samson/Getty

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Since it was first detected in December, in Wuhan, China, the number of known people infected with the coronavirus has ballooned to nearly 6,000, with new cases quickly turning up in Asia, the Americas, and Europe. As of Tuesday, 100 people have died from the illness in China, where the government is scrambling to detect it and contain the spread—speedily erecting hospitals and putting cities on shutdown mode. Other countries are curtailing international travel to China, which has agreed to allow specialists from the World Health Organization to assist in disease mitigation.

As the public health crisis becomes more serious, so too has the desire for news about the virus. Enter now, a high volume of unsourced and often inaccurate information feeding that appetite. Some of the traffic focuses on the speed of how the illness is spreading, or the response in China, but some of the most active chatter has been around potential, albeit unproven, treatments for the illness, which, because it is a virus, is unresponsive to antibiotics.

 

Some stories reported that Chinese doctors have discovered a cure for the coronavirus in a class of HIV drugs called protease inhibitors. Reuters reported that an HIV medication was being tested to treat coronavirus symptoms, but that is a far cry from any kind of cure. But then the story escalated and dubious publications like the New York Times Post and the UK-based tabloid the Express carried this claim further, saying that an HIV “wonder drug” called Nelfinavir was being used according to the Express, “‘somewhat successfully’ to tackle coronavirus.” Nelfinavir was not one of the HIV medications that was being tested, according to Reuters. Nonetheless, the internet seized on the information.  

Even though these publications are far from the mainstream, both of the articles supported their stories with apparent insights from experts in the field. One of them was Dr. Michael Mina, an epidemiologist and assistant professor at Harvard School of Public Health. The Express article said he “revealed experts…are using protease inhibitors ‘somewhat successfully’ to tackle coronavirus.”  I called Dr. Mina to find out more about this research to see how his work squares with other stories about possible coronavirus treatments mentioned in other articles.

First of all, Dr. Mina was surprised to see that he had been quoted as one of the sources for this information, since he knows that the coronavirus has no confirmed cure. In fact, during a recent conversation with a reporter at WebMD, he explicitly discussed what he described as the “unsubstantiated claims on Twitter that [protease inhibitors] were being used.” Protease inhibitors may have been used to treat SARS, a related but distinct illness, he says, but there is no evidence that these could be used for the coronavirus. 

I told Dr. Mina that he had been quoted in the Express. “I really want to know where these are coming from,” he says, adding that the conversations he’s seen on Twitter show “there’s lots of fearmongering going on about global pandemic, a catastrophe happening or about to happen.” He suggests that at this point, the only message that seems to emerge from the “tremendous amount of information being thrown around,” is that the coronavirus “is distinct from any virus from the past.”

So I asked Dr. Mina, about teasing out fact from fiction in the onslaught of information. How does one determine the seriousness of the infection, much less the cure? Officially, more than 5,900 individuals are infected with coronavirus, though some experts suspect underreporting. But, I told him, one professor at Imperial College in the United Kingdom told the Guardian that 100,000 people could have coronavirus. That number has not yet been confirmed, but Mina says that if it turns out to be true, this could be good news. A fatality rate of 100 in 100,000 is significantly lower than 100 in 2,500. “If we find out that the virus has infected many more than we know, that means it’s even less pathogenic than we think,” he says. “It would be more like seasonal flu is every year.”

What about how rapidly the coronavirus is spreading? Yet another source of misunderstanding. Across Twitter, users following the disease have paid close attention to what is known as the “r-nought”—often expressed at “R0.” That’s a data point representing the rate by which a disease spreads. To understand this better, I turned to Dr. Angela Hewlett, an infectious disease specialist at the University of Nebraska Medical Center and member of the Infectious Diseases Society of America. She explained, “It’s essentially the number of transmission events of a disease per infected person.” An r-nought of three, for example, means “one infected person is likely to infect three people.” Hewlett says that actual r-nought of this coronavirus outbreak isn’t clear. When I asked Mina, he said he thought it was somewhere between 1.5 and 3. Though, it’s important to note than the r-nought doesn’t take the severity of an illness into consideration.

In the Twitter universe, however, users are using the r-nought to calculate possible trajectories of the spread of the virus, envisioning a global pandemic, while it’s still uncertain whether the coronavirus will turn out to be more comparable to a seasonal illness like the flu in terms of mortality rates.

Not only is over-speculating on how quickly the illness is spreading unproductive and potentially fear-mongering, even a high r-nought needs to be properly contextualized. “We don’t know how many people are being infected and staying perfectly healthy throughout the process,” says Mina. Hewlett points to other prominent deadly diseases that have much higher r-noughts than coronavirus. “It’s important to put all of this in context,” Hewlett says. “Someone with measles has an r-nought of 18. Lots of diseases are much more contagious than it looks like this novel coronavirus will be.” 

The bottom line is that epidemics such as the coronavirus can often bring out the worst in social media. When tools from the science or medical worlds enter the public discourse without being fully understood, or put in context, they can be misused. “Social media allows buzzwords to enter the layperson domain,” Mina says, “which leads to a tremendous amount of misunderstanding and, frankly, fear.”

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with the Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with the Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate